Abivax stock surges 20% on positive ulcerative colitis trial
Investing.com Gold reports: Abivax stock surges 20% on positive ulcerative colitis trial. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Abivax stock surges 20% on positive ulcerative colitis trial. Full body text was unavailable at ingest time, so this brief is based on headline context.